Voyager Therapeutics, Inc. (VYGR)
After hours:
| Previous Close | 8.53 |
| Open | 8.76 |
| Bid | 8.79 x 100 |
| Ask | 8.83 x 300 |
| Day's Range | 8.61 - 8.92 |
| 52 Week Range | 6.06 - 14.34 |
| Volume | |
| Avg. Volume | 663,611 |
| Market Cap | 479.161M |
| Beta (5Y Monthly) | 0.95 |
| PE Ratio (TTM) | 2.97 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
Spotlight on new, second-generation, TRACER™-derived AAV capsids; translatability as evidenced by cross-species and receptor data; and activity against therapeutic targets in Alzheimer’s disease and ALSLEXINGTON, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will present a broad set of data related to its TRACER™ capsid discovery platform and TRACER-driven gene th
- GlobeNewswire
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
LEXINGTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease and other GBA1-mediated diseases. The candidate combines a GBA1 gene replacement payload with an intravenously a
- GlobeNewswire
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with Toby Ferguson, M.D., Ph.D. that, among other things, provides for the grant to Dr. Ferguson of a non-qualified stock option and restricted stock units as an inducement material to Dr. Ferguson’s entering into employment with Voyager. The inducement awards were approved by the Compensati
